Use of topical antibiotics as prophylaxis in clean dermatologic procedures - 18/02/12
Abstract |
Background |
Topical antibiotics are not indicated for routine postoperative care in clean dermatologic procedures, but may be widely used.
Objective |
We sought to describe topical antibiotic use in clean dermatologic surgical procedures in the United States.
Methods |
The 1993 to 2007 National Ambulatory Medical Care Survey database was queried for visits in which clean dermatologic surgery was performed. We analyzed provider specialty, use of topical antibiotics, and associated diagnoses. Use of topical antibiotic over time was analyzed by linear regression.
Results |
An estimated 212 million clean dermatologic procedures were performed between 1993 and 2007; topical antibiotics were reported in approximately 10.6 million (5.0%) procedures. Dermatologists were responsible for 63.3% of dermatologic surgery procedures and reported use of topical antibiotic prophylaxis in 8.0 million (6.0%). Dermatologists were more likely to use topical antibiotic prophylaxis than nondermatologists (6.0% vs 3.5%). Use of topical antibiotic prophylaxis decreased over time.
Limitations |
Data were limited to outpatient procedures. The assumption was made that when topical antibiotics were documented at procedure visits they were being used as prophylaxis.
Conclusions |
Topical antibiotics continue to be used as prophylaxis in clean dermatologic procedures, despite being ineffective for this purpose and posing a risk to patients. Although topical antibiotic use is decreasing, prophylactic use should be eliminated.
Le texte complet de cet article est disponible en PDF.Key words : allergic contact dermatitis, antibiotic ointment, class I wound, clean wound, dermatologic surgery, postoperative care, surgical prophylaxis, surgical site infection, surgical site infection prophylaxis, wound healing, wound infection
Abbreviations used : ACD, ICD-9, NAMCS, SSI
Plan
The Center for Dermatology Research is supported by an educational grant from Galderma Laboratories LP. This study was also supported by a grant from Glaxo-Smith-Kline. Dr Feldman has received research, speaking, and/or consulting support from Galderma, Abbott Labs, Warner Chilcott, Aventis Pharmaceuticals, 3M, Connetics, Roche, Amgen, Biogen, and Genentech. Dr Levender, Mr Davis, Mr Kwatra, and Dr Williford have no conflicts to disclose. |
Vol 66 - N° 3
P. 445 - mars 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?